Q: Sangoma released preliminary numbers for fiscal 2018 which tops guidance. Based on management's comments on the current EBITDA quarterly run rate, the the current stock price seems deeply undervalued based on EV/EBITDA with net cash on hand metric, revenue multiple and M&A history. Do you agree?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
-
Sangoma Technologies Corporation (STC $6.93)
-
Bombardier Inc. Class B Subordinate Voting Shares (BBD.B $193.35)
-
BRP Inc. Subordinate Voting Shares (DOO $92.37)
Q: These three securities listed above have all come off in a short period of time by 10% or more - do you know if there is a problem with any of them? Thanks Dennis
Q: With 3 analysts covering Sangoma now (Cormark, Beacon & Acumen), the Company seems to have all the good qualities for a small cap investment. Is it a worthy stock for the 5i growth portfolio based on its still attraction valuation?
Q: Good morning guy:
Could you please provide your opinion on this name please. Is it a buy for a long term hold?
Thanks
Mark
Could you please provide your opinion on this name please. Is it a buy for a long term hold?
Thanks
Mark
Q: What did you think of their recent quarterly results? I thought earnings looked good after taking out the one time acquisition costs. What are you thoughts?
-
BioSyent Inc. (RX $11.70)
-
Sangoma Technologies Corporation (STC $6.93)
-
Dynacor Group Inc. (DNG $4.55)
-
VersaBank (VBNK $17.01)
Q: My small cap holdings consist of:
Biosyent (RX), Versa Bank (VB), Sangoma (STC), and Dynacor Gold (DNG)
If you were going to add to one of these which would it be and why?
Would you sell any of these today?
Thanks.
Biosyent (RX), Versa Bank (VB), Sangoma (STC), and Dynacor Gold (DNG)
If you were going to add to one of these which would it be and why?
Would you sell any of these today?
Thanks.
Q: any idea what is going on with this company? big volume yesterday and price weakness?
thanks
Don
thanks
Don
Q: Hi 5i:
Do you think its wise to build a bigger position in Sangoma Technologies now (as part of a growth portfolio) given that the Company has cashed up following the closing of a bought deal financing with institutional investors? The Company has a history of making profitable acquisitions.
Do you think its wise to build a bigger position in Sangoma Technologies now (as part of a growth portfolio) given that the Company has cashed up following the closing of a bought deal financing with institutional investors? The Company has a history of making profitable acquisitions.
Q: I noticed that Sangoma Technologies Q2 results came in quite a bit higher than both analyst estimates. Would you expect target upgrades forthcoming and therefore a positive impact on the stock price?
Q: Hi there,
Thanks for your great service. Could I please have your opinion on the Q results from Sangoma?
Thanks!
Thanks for your great service. Could I please have your opinion on the Q results from Sangoma?
Thanks!
Q: Hi Peter , can you please help me out to understand this two co . My risk factor and their recent reports . Would it be a buy in cash acct. I also have room in my tfac acct.Thanks . Alnoor
Q: Sangoma Technologies seems to finally getting the attention it deserves. It was recently a Top Pick on BNN - Market Call. Despite the stock price run up as of late, is it still a buy based on current valuation levels, analyst targets and fiscal 2019 expected results?
Q: What are your thoughts about Sangoma's acquisition this morning? Stock seems very undervalued. Will bigger investors start looking at this Company now, given the analyst coverage, and 12 months sales over $60 million and and very profitable?
Q: I hear Cormark Securities started research coverage on Sangoma Technologies today with a Buy $1.50 target. Beacon Securities already covers the Company with a Buy $1.55 target. Do you think the addition of Cormark will get more attention to the stock given the stellar results and a very cheap current stock valuation? In other words does 2 analysts make a difference now?
Q: Sangoma Technologies released Q1 FY 2018 results this evening. Q1 looked really strong and the share valuation seems very inexpensive for Company with this growth rate, that is profitable and has a strong balance sheet. Your thoughts on STC, its current valuation and would it be a future consideration for the 5i growth portfolio given its 2018 annual sales are guided to exceed $46 million?
Q: What was the consensus for Q1's sales ebitda and eps?
Also, please comment on the Q.
thanks
Also, please comment on the Q.
thanks
Q: Can you please comment on YE results and 2018 guidance just released? What do you think about the company's valuation and growth outlook? Thanks
Q: Can you comment on STC's preliminary q4 numbers. How does the company look go foward? Thanks
-
Sangoma Technologies Corporation (STC $6.93)
-
Helius Medical Technologies Inc. Class A common shares (HSM $18.35)
-
Pioneering Technology Corp. (PTE $0.02)
-
TeraGo Inc. (TGO $0.82)
Q: these four stocks and two others symbols AT and PTO
How would you rate them from best to least and are they worth the risk for a risk based long term growth portfolio
How would you rate them from best to least and are they worth the risk for a risk based long term growth portfolio
Q: Hello 5i,
There appears to be a large seller dumping shares of STC through a TD brokerage account. I noticed other insiders had been buyers very recently in the low 80 cent range. Do you think this is a decent opportunity to buy some shares on the dip? I currently have a half position in STC as part of a small/micro cap growth portfolio. Thanks.
There appears to be a large seller dumping shares of STC through a TD brokerage account. I noticed other insiders had been buyers very recently in the low 80 cent range. Do you think this is a decent opportunity to buy some shares on the dip? I currently have a half position in STC as part of a small/micro cap growth portfolio. Thanks.